Rockwell Medical (RMTI) Cash & Equivalents (2010 - 2026)

Rockwell Medical has reported Cash & Equivalents for 17 years, with the latest figure at $9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 15.64% year-over-year to $9.6 million; the trailing twelve-month figure through Mar 2026 stood at $9.6 million (down 15.64% YoY), and the FY2025 full-year result was $10.7 million, down 31.61% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $9.6 million, down from $10.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $30.8 million in Q2 2022, with the low at $6.6 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $12.0 million across 5 years, with a median of $10.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 72.25% — and 2024, when it jumped 74.35%.
• Rockwell Medical's Cash & Equivalents stood at $10.1 million in 2022, then decreased by 11.08% to $9.0 million in 2023, then soared by 74.35% to $15.7 million in 2024, then slumped by 31.61% to $10.7 million in 2025, then dropped by 10.29% to $9.6 million in 2026.
• The last three Cash & Equivalents figures came in at $9.6 million (Q1 2026), $10.7 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.